SR-8541A

DRUG2 trials

Sponsors

Stingray Therapeutics

Conditions

Advanced / Metastatic Solid TumorRefractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Phase 1

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

RecruitingNCT06063681

Stingray TherapeuticsAdvanced / Metastatic Solid Tumor

Start: 2023-10-12End: 2025-12-31Target: 25Updated: 2025-06-08

Phase 2

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

RecruitingNCT06589440

Stingray TherapeuticsRefractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Start: 2024-11-20End: 2027-07-31Target: 70Updated: 2026-08-12

Related Papers

Abstract CT221: A progress report for a Phase 1b/2 study of ENPP1 inhibitor, vizenpistat in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer

Cancer Research2026-04-17

Abstract CT200: Phase I dose-escalation study of ENPP1 inhibitor, vizenpistat, for the treatment of solid tumors

Cancer Research2026-04-17

A phase 2 study of SR-8541A in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer (MSS-CRC).

Journal of Clinical Oncology2025-05-28

Abstract CT240: A phase 2 study of SR-8541A in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer (MSS-CRC)

Cancer Research2025-04-25

Abstract CT161: First-in-human study of ENPP1 inhibitor, SR-8541A, for the treatment of solid tumors

Cancer Research2024-04-051 citations